Aqua Pharmaceuticals Acquires US Rights to Veltin Gel and Altabax Ointment

December 1, 2015

Aqua Pharmaceuticals, LLC acquired the US rights to two dermatology products— Veltin (clindamycin phosphate and tretinoin) Gel 1.2%/0.025% and Altabax (retapamulin) Ointment 1%, after Almirall, parent company of Aqua, acquired the rights to the products from GlaxoSmithKline. Both Veltin and Altabax will be promoted through Aqua in the United States.

Veltin is a prescription combination product containing clindamycin and tretinoin indicated for the topical treatment of acne vulgaris in patients 12 years of age and older.

Altabax is a topical antibiotic indicated for the treatment of the skin infection impetigo due to susceptible strains of Staphylococcus aureus or Staphylococcus pyogenes in adults and pediatric patients 9 months of age or older.


Facebook Comments


We’re glad to see you’re enjoying PracticalDermatology…
but how about a more personalized experience?

Register for free